Clinical features and 28-day mortality predictors of vaccinated patients admitted to a COVID-19 ICU hub in Italy.
COVID-19
Intensive care unit
Mortality
Vaccination
Journal
Journal of anesthesia, analgesia and critical care
ISSN: 2731-3786
Titre abrégé: J Anesth Analg Crit Care
Pays: England
ID NLM: 9918591885906676
Informations de publication
Date de publication:
13 Nov 2023
13 Nov 2023
Historique:
received:
13
09
2023
accepted:
26
10
2023
medline:
14
11
2023
pubmed:
14
11
2023
entrez:
14
11
2023
Statut:
epublish
Résumé
COVID-19 vaccination has been proved to be effective in preventing hospitalization and illness progression, even though data on mortality of vaccinated patients in the intensive care unit (ICU) are conflicting. The aim of this study was to investigate the characteristics of vaccinated patients admitted to ICU according to their immunization cycle and to outline the risk factors for 28-day mortality. This observational study included adult patients admitted to ICU for acute respiratory failure (ARF) due to SARS-CoV-2 and who had received at least one dose of vaccine. Fully vaccination was defined as a complete primary cycle from < 120 days or a booster dose from > 14 days. All the other patients were named partially vaccinated. One-hundred sixty patients (91 fully and 69 partially vaccinated) resulted eligible, showing a 28-day mortality rate of 51.9%. Compared to partially vaccinated, fully vaccinated were younger (69 [60-77.5] vs. 74 [66-79] years, p 0.029), more frequently immunocompromised (39.56% vs. 14.39%, p 0.003), and affected by at least one comorbidity (90.11% vs 78.26%, p 0.045), mainly chronic kidney disease (CKD) (36.26% vs 20.29%, p 0.035). At multivariable analysis, independent predictors of 28-day mortality were as follows: older age [OR 1.05 (CI 95% 1.01-1.08), p 0.005], history of chronic obstructive pulmonary disease (COPD) [OR 3.05 (CI 95% 1.28-7.30), p 0.012], immunosuppression [OR 3.70 (CI 95% 1.63-8.40), p 0.002], and admission respiratory and hemodynamic status [PaO Despite a full vaccination cycle, severe COVID-19 may occur in patients with relevant comorbidities, especially immunosuppression and CKD. Regardless the immunization status, predisposing conditions (i.e., older age, COPD, and immunosuppression) and a severe clinical presentation were predictors of 28-day mortality.
Sections du résumé
BACKGROUND
BACKGROUND
COVID-19 vaccination has been proved to be effective in preventing hospitalization and illness progression, even though data on mortality of vaccinated patients in the intensive care unit (ICU) are conflicting. The aim of this study was to investigate the characteristics of vaccinated patients admitted to ICU according to their immunization cycle and to outline the risk factors for 28-day mortality. This observational study included adult patients admitted to ICU for acute respiratory failure (ARF) due to SARS-CoV-2 and who had received at least one dose of vaccine.
RESULTS
RESULTS
Fully vaccination was defined as a complete primary cycle from < 120 days or a booster dose from > 14 days. All the other patients were named partially vaccinated. One-hundred sixty patients (91 fully and 69 partially vaccinated) resulted eligible, showing a 28-day mortality rate of 51.9%. Compared to partially vaccinated, fully vaccinated were younger (69 [60-77.5] vs. 74 [66-79] years, p 0.029), more frequently immunocompromised (39.56% vs. 14.39%, p 0.003), and affected by at least one comorbidity (90.11% vs 78.26%, p 0.045), mainly chronic kidney disease (CKD) (36.26% vs 20.29%, p 0.035). At multivariable analysis, independent predictors of 28-day mortality were as follows: older age [OR 1.05 (CI 95% 1.01-1.08), p 0.005], history of chronic obstructive pulmonary disease (COPD) [OR 3.05 (CI 95% 1.28-7.30), p 0.012], immunosuppression [OR 3.70 (CI 95% 1.63-8.40), p 0.002], and admission respiratory and hemodynamic status [PaO
CONCLUSIONS
CONCLUSIONS
Despite a full vaccination cycle, severe COVID-19 may occur in patients with relevant comorbidities, especially immunosuppression and CKD. Regardless the immunization status, predisposing conditions (i.e., older age, COPD, and immunosuppression) and a severe clinical presentation were predictors of 28-day mortality.
Identifiants
pubmed: 37957713
doi: 10.1186/s44158-023-00130-6
pii: 10.1186/s44158-023-00130-6
pmc: PMC10644635
doi:
Types de publication
Journal Article
Langues
eng
Pagination
47Informations de copyright
© 2023. The Author(s).
Références
Infect Dis Clin North Am. 2022 Jun;36(2):365-377
pubmed: 35636905
JAMA. 2022 Feb 15;327(7):639-651
pubmed: 35060999
Clin Chest Med. 2023 Jun;44(2):395-406
pubmed: 37085228
Prev Med. 2022 Oct;163:107237
pubmed: 36057393
J Infect Dis. 2023 Apr 18;227(8):961-969
pubmed: 36415904
JAMA Netw Open. 2022 Oct 3;5(10):e2238871
pubmed: 36301541
Med Sci (Basel). 2022 Dec 04;10(4):
pubmed: 36548002
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
J Clin Med. 2023 Feb 22;12(5):
pubmed: 36902535
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Ann Palliat Med. 2023 May 08;:
pubmed: 37164968
J Biomed Sci. 2022 Oct 15;29(1):82
pubmed: 36243868
N Engl J Med. 2022 Jan 27;386(4):340-350
pubmed: 35021002
Nat Commun. 2022 Aug 8;13(1):4615
pubmed: 35941158
Indian J Crit Care Med. 2022 Nov;26(11):1184-1191
pubmed: 36873595
J Clin Med. 2021 Aug 15;10(16):
pubmed: 34441891
Rev Esp Anestesiol Reanim (Engl Ed). 2020 Oct;67(8):425-437
pubmed: 32800622
BMJ. 2022 Mar 9;376:e069761
pubmed: 35264324
Ageing Res Rev. 2023 Feb;84:101832
pubmed: 36565961
JAMA Intern Med. 2020 Oct 1;180(10):1345-1355
pubmed: 32667669
Lancet. 2022 Mar 5;399(10328):924-944
pubmed: 35202601
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
JAMA. 2021 Nov 23;326(20):2043-2054
pubmed: 34734975
Int J Infect Dis. 2022 Sep;122:420-426
pubmed: 35750265
Transpl Int. 2021 Oct;34(10):1776-1788
pubmed: 34450686
Am J Transplant. 2022 Jan;22(1):322-323
pubmed: 34331842
JAMA Netw Open. 2022 May 2;5(5):e2213553
pubmed: 35608862
Expert Rev Vaccines. 2022 Apr;21(4):423-425
pubmed: 34962214
Prog Cardiovasc Dis. 2023 Jan-Feb;76:3-11
pubmed: 36693489
BMJ. 2022 Mar 2;376:e068632
pubmed: 35236664
J Clin Med. 2022 Jul 15;11(14):
pubmed: 35887864
Healthcare (Basel). 2023 Jan 19;11(3):
pubmed: 36766880
JAMA Intern Med. 2020 Nov 1;180(11):1436-1447
pubmed: 32667668
Eur Respir J. 2022 Feb 10;59(2):
pubmed: 34824059
Am J Transplant. 2021 Aug;21(8):2719-2726
pubmed: 33866672
Front Med (Lausanne). 2022 Nov 24;9:1042411
pubmed: 36507545
J Infect Public Health. 2022 Jun;15(6):670-676
pubmed: 35617831
J Infect. 2022 May;84(5):675-683
pubmed: 34990709
Sci Rep. 2021 Feb 19;11(1):4263
pubmed: 33608563
Intensive Care Med. 2022 Jun;48(6):690-705
pubmed: 35596752
J Clin Med. 2022 May 04;11(9):
pubmed: 35566691
Br J Cancer. 2022 Nov;127(10):1827-1836
pubmed: 36224402
Am J Respir Crit Care Med. 2021 Jan 1;203(1):24-36
pubmed: 33146552
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
Am J Transplant. 2022 Mar;22(3):801-812
pubmed: 34860470
Med Intensiva (Engl Ed). 2022 Oct;46(10):588-590
pubmed: 35879183